主页文献库搜索
Pharmacokinetic (PK) and clinical phase II trial of imatinib in patients with...

Eckel(F),von Delius(S),Dobritz(M),Fend(F),... J Clin Oncol 0000-00-00

...mos and 3.7 mos in pts with SD. In pts treated with 400 mg imatinib there were no significant differences in PKs (t 22.0...

Cetuximab with oxaliplatin and capecitabine (CAPOX)in patients with metastati...

Grothe(W),Arnold(D),Peinert(S),Voigt(W),Ma... J Clin Oncol 0000-00-00

...mos (0.25+-9.6), median overall survival is 5.5+ mos (0.6-10.9+) (7 pts ongoing).,Combination of Cetuximab plus CAPOX ha...

Pilot study of celecoxib in oral premalignant lesions (OPLs): Preliminary res...

Wirth(L J),Moran(A E),Krane(J F),Weeks(L),... J Clin Oncol 0000-00-00

...mos, when biopsies were repeated.,18 patients are evaluable at 3 mos, 10 at 12 mos. One patient was withdrawn for gr 2 a...

Outcome of patients with advanced non-small-cell lung cancer and ECOG perform...

Gebbia(V),Galetta(D),Lorusso(V),Colucci(G)... J Clin Oncol 0000-00-00

...mos (1-13.5 mos) with a 6-month progression-free probability rate of 43%. This difference in median TTP was highly signi...

Multi-drug chemotherapy for pancreatic cancer.

Bruckner(H W),Myo(M),Zaw(K),Filipova(O),He... J Clin Oncol 0000-00-00

...mos on adding 80 mg/M of Irinotecan to a 'failed' q2 wk Gemzar-Fluorouracil-Cisplatin regimen (The Oncologist 6:488 2001...

An alternative schedule of oral vinorelbine tested as 2-line treatment on eld...

de Petris(L),Migliorino(M R),de Santis(S),... J Clin Oncol 0000-00-00

...mos; actuarial median OS (events:61%): 4 mos. Evaluation of clinical benefit is ongoing.,The weekly schedule of O-VNB is...

The impact and perception of mandatory tumor biopsies (Bx) for correlative st...

Agulnik(M),Oza(A M),Pond(G R),Siu(L L) J Clin Oncol 0000-00-00

...MOs responded. Correlative testing of bx specimens was considered worthwhile by 96% of MOs. Clinical trials with mandato...

Cost effectiveness of androgen suppression plus radiation therapy for clinica...

Wang(S J),Herman(T S),Thomas(C R) J Clin Oncol 0000-00-00

...mos of AST, for pts with clinically localized prostate cancer. Quality-of-life utility measures and cost data were obtai...

Gemcitabine and cisplatin (GC) for metastatic breast cancer (BC).

Gerson(R),Fuentes(H),Serrano(A),Villalobos(A) J Clin Oncol 0000-00-00

...mos, range 2 to 15. Mean TTPd 7.9 +/- 4.0 mos, range: 2 - 20. Twelve deaths has been registered (63.1%). Mean survival: ...

Efficacy and influence of neoadjuvant epirubicin/vinorelbine chemotherapy (EN...

Brandi(M),Cataldi(A),Di Corato(G),Altieri(... J Clin Oncol 0000-00-00

886 Background: IBC is the most aggressive form of breast cancer. The introduction of chemotherapy(CT) in multimodality ...

上一页 696 697 698 699 700 701 702 703 704 下一页 700 / 共 704

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: [email protected]